TY - JOUR T1 - Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus JF - medRxiv DO - 10.1101/2020.02.22.20025460 SP - 2020.02.22.20025460 AU - Tieying Hou AU - Weiqi Zeng AU - Minling Yang AU - Wenjing Chen AU - Lili Ren AU - Jingwen Ai AU - Ji Wu AU - Yalong Liao AU - Xuejing Gou AU - Yongjun Li AU - Xiaorui Wang AU - Hang Su AU - Bing Gu AU - Jianwei Wang AU - Teng Xu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/25/2020.02.22.20025460.abstract N2 - Background The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third zoonotic CoV has raised great public health concern. The demand for rapid and accurate diagnosis of this novel pathogen brought significant clinical and technological challenges. Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) are the most widely used molecular diagnostics for 2019-nCoV.Methods 2019-nCoV infections were confirmed in 52 specimens by mNGS. Genomic information was analyzed and used for the design and development of an isothermal, CRISPR-based diagnostic for the novel virus. The diagnostic performance of CRISPR-nCoV was assessed and also compared across three technology platforms (mNGS, RT-PCR and CRISPR)Results 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared certain genetic similarity with SARS-CoV. A high degree of variation in the level of viral RNA was observed in clinical specimens. CRISPR-nCoV demonstrated a near single-copy sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR.Conclusion CRISPR-nCoV presents as a promising diagnostic option for the emerging pathogen.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Major Science & Technology Project for Control and Prevention of Major Infectious Diseases in China; Guangdong Science and Technology Department ;Guangzhou Science, Technology and Innovation CommissionAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata unavailable ER -